| Autor: |
Jemutai J; AkiliNook Research and Consulting, Kilifi, Kenya., Downs L; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Anderson M; Africa Health Research Institute, KwaZulu-Natal, South Africa; The Francis Crick Institute, London NW1 1AT, UK; Botswana Harvard Health Partnership, Gaborone, Botswana., Cohen C; Hepatitis B Foundation, Doylestown, PA, USA., Seeley J; Africa Health Research Institute, KwaZulu-Natal, South Africa; Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK., Sultan B; Collaborative Centre for Inclusion Health, University College London, London, UK; Bloomsbury Clinic, Central and North West London NHS Foundation Trust, London, UK., Ko J; Bloomsbury Clinic, Central and North West London NHS Foundation Trust, London, UK., Flanagan S; Division of Infection and Immunity, University College London, London, UK; Bloomsbury Clinic, Central and North West London NHS Foundation Trust, London, UK; Department of Infectious Diseases, University College London Hospital, London, UK., Iwuji C; Africa Health Research Institute, KwaZulu-Natal, South Africa; Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, UK., Halford R; World Hepatitis Alliance, London, UK., Fernandes O; Clinton Healthcare Access Initiative, Boston, MA, USA., Vickerman P; Faculty of Health and Life Sciences, University of Bristol, Bristol, UK., Johannessen A; Centre for Global Health, Sustainable Health Unit, University of Oslo, Oslo, Norway., Matthews PC; The Francis Crick Institute, London NW1 1AT, UK; Division of Infection and Immunity, University College London, London, UK; Bloomsbury Clinic, Central and North West London NHS Foundation Trust, London, UK; Department of Infectious Diseases, University College London Hospital, London, UK. Electronic address: philippa.matthews@crick.ac.uk. |
| Abstrakt: |
Competing Interests: PCM receives funding from the Francis Crick Institute (CC2223); University College London Hospitals National Institute for Health and Care Research Biomedical Research Centre; and has received funding from GSK, to support a PhD fellowship in her team. LD is funded by a Wellcome Doctoral Fellowship (225485/Z/22/Z). BS is funded by a National Institute of Health Research Doctoral Research Fellowship (DRF-2018–11-ST2–050), paid to University College London. CI has received honoraria, financial support to attend conferences, and research funding from Gilead Sciences, paid to the University of Sussex. CC is on patient advisory councils for GSK and Gilead Sciences, paid to the Hepatitis B Foundation. SF has received a research grant from British HIV Association–Gilead Sciences; has received honoraria and travel support from Gilead Sciences, Viiv Healthcare, and MSD; and has been a chair for a British Association for Sexual Health and HIV–Blood Borne Viruses special interest group and a British HIV Association guidelines subcommittee. PV has received funding from Gilead Sciences. The Hepatitis B Foundation receives educational and programme grants from Gilead Sciences, GSK, Vir Biotechnology, Precision BioSciences, and Roche. All other authors declare no competing interests. |
